Atlas Venture Life Science Advisors, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 6, 2024), Atlas Venture Life Science Advisors, LLC reported 16 stock positions worth $1.1 billion. Its top holding was Dyne Therapeutics (DYN) at 21.0% of the portfolio, followed by Kymera Therapeutics (KYMR, 19.9%) and Disc Medicine (IRON, 13.1%). Compared with Q4 2023, it opened 1 new position, sold out of 1 and reduced 7. The biggest buy was a new position in Q32 Bio (QTTB) and the biggest sale Disc Medicine (IRON, shares −10%).
- Most Recent 13F
- Q2 2026
- Location
- CAMBRIDGE, MA
- CIK
- 0001917529
- Portfolio Value
- $1.1B (Q1 2024)
- SEC Filing
- 0001104659-24-057096 ↗ filed May 6, 2024
Holdings Value
Holdings 16 stocks · $1.1B
| DYN Dyne Therapeutics Inc. | 21.01% | 8,020,136 | $227.7M | Reduce -18.9% |
| KYMR Kymera Therapeutics Inc. | 19.95% | 5,377,362 | $216.2M | Reduce -8.2% |
| IRON Disc Medicine Inc. | 13.14% | 2,287,233 | $142.4M | Reduce -10.5% |
| DAWN Day One Biopharmaceuticals I | 9.80% | 6,430,257 | $106.2M | Reduce -15.5% |
| THRD Third Harmonic Bio Inc. | 9.50% | 10,907,859 | $103.0M | No change |
| KRRO Korro Bio Inc. | 9.30% | 1,119,292 | $100.7M | No change |
| AEROVATE THERAPEUTICS INC | 5.57% | 2,039,249 | $60.3M | No change |
| QTTB Q32 Bio Inc. | 3.29% | 2,092,106 | $35.6M | New |
| GBIO Generation Bio Co. | 3.11% | 8,279,484 | $33.7M | No change |
| VIGL Vigil Neuroscience Inc. | 1.84% | 5,836,874 | $19.9M | No change |
| REPL Replimune Group Inc. | 1.58% | 2,098,300 | $17.1M | No change |
| IKENA ONCOLOGY INC | 0.66% | 5,018,178 | $7.1M | No change |
| AVROBIO INC | 0.54% | 4,541,381 | $5.8M | No change |
| DNTH Dianthus Therapeutics Inc. | 0.52% | 186,979 | $5.6M | Reduce -21.1% |
| XLO Xilio Therapeutics Inc. | 0.10% | 992,912 | $1.1M | Reduce -64.0% |
| SPRO Spero Therapeutics Inc. | 0.10% | 607,613 | $1.0M | Reduce -40.0% |
Portfolio Sells Q4 2023 → Q1 2024
| IRON Disc Medicine Inc. | Reduce -10.5% | 13.14% | −4.43 |
| DAWN Day One Biopharmaceuticals I | Reduce -15.5% | 9.80% | −3.42 |
| AKRO Akero Therapeutics Inc. | Sold out | 0.00% | −1.00 |
| XLO Xilio Therapeutics Inc. | Reduce -64.0% | 0.10% | −0.08 |
| SPRO Spero Therapeutics Inc. | Reduce -40.0% | 0.10% | −0.08 |
| DNTH Dianthus Therapeutics Inc. | Reduce -21.1% | 0.52% | +0.22 |
| KYMR Kymera Therapeutics Inc. | Reduce -8.2% | 19.95% | +2.19 |
| DYN Dyne Therapeutics Inc. | Reduce -18.9% | 21.01% | +5.36 |
Portfolio Buys Q4 2023 → Q1 2024
| QTTB Q32 Bio Inc. | New | 3.29% | +3.29 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 7 | $881.3M | KYMR, DYN, SION, KLRA, IRON |
| Q1 2026 | 6 | $790.0M | KYMR, DYN, SION, IRON, QTTB |
| Q4 2025 | 8 | $865.2M | KYMR, DYN, SION, IRON, DAWN |
| Q3 2025 | 9 | $752.6M | KYMR, IRON, DYN, SION, KRRO |
| Q2 2025 | 11 | $662.4M | KYMR, IRON, DYN, SION, THRD |
| Q1 2025 | 13 | $521.8M | KYMR, IRON, DYN, DAWN, SION |
| Q4 2024 | 13 | $819.7M | KYMR, DYN, IRON, THRD, DAWN |
| Q3 2024 | 14 | $1.1B | DYN, KYMR, THRD, IRON, QTTB |
| Q2 2024 | 15 | $949.6M | DYN, KYMR, THRD, IRON, DAWN |
| Q1 2024 | 16 | $1.1B | DYN, KYMR, IRON, DAWN, THRD |